The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’), the developer of therapeutic cancer and infectious disease vaccines based on its patented ImmunoBody® platform, are pleased to announce the preliminary results for Scancell for the year ended 30th April 2009 (‘the Period’).
Post Period Highlights:
David Evans, Non-Executive Chairman of Scancell, commented:
“I am pleased to report on Scancell’s first successful year as a public company. The Company continues to make good progress towards commencing Phase 1 clinical trials on its first therapeutic cancer vaccine SCIB1 in 2010..Scancell has also entered into a number of significant agreements that will support both SCIB1 and the development of future ImmunoBody® vaccines.”
For further information contact:
Professor Lindy Durrant - Scancell Holdings Plc - +44 207 245 1100
Adam Reynolds/Vikki Krause - Hansard Group - +44 7515 922906
Ross Andrews - Zeus Capital - +44 (0)161 831 1512
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00
Sign up to our newsletter to stay up to date with Scancell